Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2025, ...

Every investor in Abbott Laboratories (NYSE:ABT) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 80% ownership. In ...

Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company ...

Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

US Dollar Canadian Dollar, Nasdaq 100, S&P 500, Goldman Sachs Group Inc. Read 's Market Analysis on Investing.com CA.

Abbott second-quarter results came in ahead of the consensus forecast, with its Medical Device business growing 13.4%.

CEO Robert Ford cited his company’s latest quarterly report, telling reporters that Wall Street’s reaction to the results was extreme. “I think this is a little bit of an overreaction. Of course, we ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.